Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allurion Technologies, Inc. Common Stock (NY: ALUR )

14.65 +10.95 (+295.95%)
Streaming Delayed Price Updated: 9:30 AM EST, Jan 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Allurion Technologies, Inc. Common Stock

< Previous 1 2 Next >
Allurion to Raise Approximately $7.4 Million of Gross Proceeds in Offering Priced At-the-Market
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Plans To Optimize Muscle Mass During GLP-1 Therapy In Combination With the Allurion Program
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Notification of Issuance of New U.S. Patent on Next-Generation Weight Loss Device for the Treatment of Obesity
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Private Placement of Common Stock and Preliminary Unaudited Financial Results for the Fourth Quarter and Fiscal Year 2024
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Positive Topline Results From AUDACITY Trial
From Allurion Technologies, Inc.
Via Business Wire
Allurion Technologies, Inc. Announces Reverse Stock Split
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces NYSE Acceptance of Plan to Regain Listing Compliance
From Allurion Technologies, Inc.
Via Business Wire
Allurion Launches in the US with its First AI-Native Compounded GLP-1 Program
From Allurion Technologies, Inc.
Via Business Wire
Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update
From Allurion Technologies, Inc.
Via Business Wire
Allurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Society’s Annual Conference
From Allurion Technologies, Inc.
Via Business Wire
Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss
From Allurion Technologies, Inc.
Via Business Wire
October's 4 Best Penny Stocks: High-Risk, High-Reward Picks
Penny stocks are a risky but potentially rewarding opportunity for investors willing to take on their uncertainty; these stocks may stand out from the pack. 
Via MarketBeat
Topics Bankruptcy
Exposures Financial Legal
Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss
From Allurion Technologies, Inc.
Via Business Wire
Allurion Receives Continued Listing Standards Notice from NYSE
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Publication of New Data Demonstrating Weight Loss in Adolescents Suffering from Obesity
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces the Appointment of Eli Lilly Veteran, Keith Johns, to Its Board of Directors
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Publication of New Data Demonstrating Continued Weight Loss at One Year On the Allurion Program
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces the Appointment of Adrian Wild as Senior Vice President, International Commercial
From Allurion Technologies, Inc.
Via Business Wire
Allurion Receives Continued Listing Standards Notice from NYSE
From Allurion Technologies, Inc.
Via Business Wire
Allurion Reports Second Quarter 2024 Financial Results and Provides Business Update
From Allurion Technologies, Inc.
Via Business Wire
Allurion to Report Second Quarter 2024 Financial Results on August 13, 2024
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Pricing of $20 million Public Offering and Concurrent Private Placement
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Launch of Offering of Common Stock and Warrants
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Publication of New Data Demonstrating Lean Mass Gains in Patients Experiencing 14% Weight Loss
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Three Scientific Presentations at the 40th Annual Meeting of the American Society for Metabolic and Bariatric Surgery
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces the Appointment of Ojas A. Buch as Chief Operating Officer
From Allurion Technologies, Inc.
Via Business Wire
Allurion Announces Expansion of AI Weight Loss Coach to Support Patients on GLP-1s
From Allurion Technologies, Inc.
Via Business Wire
Allurion to Participate in Two Upcoming Investor Conferences in June 2024
From Allurion Technologies, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.